27 Results

People

  1. Motzer
    Motzer
  2. Makker
    Makker
  3. Abou-Alfa
    Abou-Alfa
  4. Aghajanian
    Aghajanian
  5. Chi
    Chi
  6. Armstrong
    Armstrong
  7. Avutu
    Avutu
  8. Banks
    Banks
  9. Baxi
    Baxi
  10. Boucai
    Boucai

Groups

  1. Department of Medicine (22)
  2. Solid Tumor Oncology Division (21)
  3. Genitourinary Oncology Service (9)
  4. GDMT, Medicine (7)
  5. Gynecologic Medicine Service (7)
  6. Gynecology Disease Management Team (7)
  7. Gastrointestinal Oncology Service (4)
  8. Center for Pancreatic Cancer Research (3)
  9. GSK Faculty (3)
  10. Surgery (3)
  1. "carbanilamide derivative"
Formats
  1. Journal Article (24)
  2. Review (2)
  3. Correspondence (1)
Groups
  1. Department of Medicine (22)
  2. Solid Tumor Oncology Division (21)
  3. Genitourinary Oncology Service (9)
  4. GDMT, Medicine (7)
  5. Gynecologic Medicine Service (7)
  6. Gynecology Disease Management Team (7)

More Groups

People
  1. Robert Motzer (9)
  2. Vicky Makker (6)
  3. Ghassan Abou-Alfa (3)
  4. Carol Aghajanian (2)
  5. Ping Chi (2)
  6. Alan Ho (1)

More People

Years
  1. 2025 (2)
  2. 2024 (10)
  3. 2023 (2)
  4. 2022 (6)
  5. 2021 (2)
  6. 2020 (1)

More Years

Publications
  1. Journal of Clinical Oncology (3)
  2. Clinical Cancer Research (2)
  3. International Journal of Cancer (2)
  4. Lancet Oncology (2)
  5. New England Journal of Medicine (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. Elsevier Science, Inc. (4)
  2. American Association for Cancer Research (3)
  3. American Society of Clinical Oncology (3)
  4. Elsevier Inc. (2)
  5. John Wiley & Sons (2)
  6. Massachusetts Medical Society (2)

More Publishers

Results (27)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarker analyses from the phase III randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Grünwald, V.; George, S.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial
    Journal Article

    Grünwald, V.; McKay, R. R.; Buchler, T.; Eto, M.; Park, S. H.; Takagi, T.; Zanetta, S.; Keizman, D.; Suárez, C.; Négrier, S.; more...
    International Journal of Cancer (2025)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Phase 2 trial of regorafenib in recurrent/metastatic adenoid cystic carcinoma
    Journal Article

    Desilets, A.; Vos, J. L.; Katabi, N.; Kuo, F.; Nadeem, Z.; Linxweiler, M.; Ostrovnaya, I.; Baxi, S.; Dunn, L. A.; Sherman, E. J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: Results of the phase 3 TiNivo-2 study
    Journal Article

    Choueiri, T. K.; Albiges, L.; Barthélémy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P.; Basu, A.; Bourlon, M. T.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Characterization of responses to lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma at the final prespecified survival analysis of the phase 3 CLEAR study
    Journal Article

    Motzer, R. J.; Choueiri, T. K.; Hutson, T.; Young Rha, S.; Puente, J.; Lalani, A. K. A.; Winquist, E.; Eto, M.; Basappa, N. S.; Tannir, N. M.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • CALGB 80802 (Alliance): Impact of sorafenib with and without doxorubicin on hepatitis C infection in patients with advanced hepatocellular carcinoma
    Journal Article

    Abou-Alfa, G. K.; Geyer, S. M.; Nixon, A. B.; Innocenti, F.; Shi, Q.; Kumthekar, P.; Jacobson, S.; El Dika, I.; Yaqubie, A.; Lopez, J.; more...
    Cancer Research Communications (2024)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: Final prespecified overall survival analysis of CLEAR, a phase III study
    Journal Article

    Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grünwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Merchan, J.; Goh, J. C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
    Journal Article

    Lee, V.; Parkinson, R.; Zahurak, M.; Cope, L.; Cercek, A.; Verheul, H.; Gootjes, E.; Lenz, H. J.; Iqbal, S.; Jones, P.; more...
    International Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Analysis of East Asia subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer
    Journal Article

    Yonemori, K.; Fujiwara, K.; Hasegawa, K.; Yunokawa, M.; Ushijima, K.; Suzuki, S.; Shikama, A.; Minobe, S.; Usami, T.; Kim, J. W.; more...
    Journal of Gynecologic Oncology (2024)

    Fulltext@MSK | Save